Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series

Biliński, Jarosław; Jasiński, Marcin; Tomaszewska, Agnieszka; Lis, Karol; Kacprzyk, Piotr; Chmielewska, Lidia; Karakulska-Prystupiuk, Ewa; Mullish, Benjamin H.; Basak, Grzegorz W.

doi:10.1002/ajh.26365

Cited by 16 publications

(9 citation statements)

References 5 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies confirmed these findings [ 193 , 197 , 199 , 206 , 207 ]. Also, Bilinski’s team have shown the promising results of FMT as an immunomodulatory agent in the treatment of acute gastrointestinal graft-versus-host disease [ 208 , 209 ] what was confirmed in other groups [ 210 ].…”

Section: Therapeutic Strategies In the Gut Microbiota Manipulationmentioning

confidence: 80%

Microbiota medicine: towards clinical revolution

Gebrayel¹,

et al. 2022

View full text Add to dashboard Cite

The human gastrointestinal tract is inhabited by the largest microbial community within the human body consisting of trillions of microbes called gut microbiota. The normal flora is the site of many physiological functions such as enhancing the host immunity, participating in the nutrient absorption and protecting the body against pathogenic microorganisms. Numerous investigations showed a bidirectional interplay between gut microbiota and many organs within the human body such as the intestines, the lungs, the brain, and the skin. Large body of evidence demonstrated, more than a decade ago, that the gut microbial alteration is a key factor in the pathogenesis of many local and systemic disorders. In this regard, a deep understanding of the mechanisms involved in the gut microbial symbiosis/dysbiosis is crucial for the clinical and health field. We review the most recent studies on the involvement of gut microbiota in the pathogenesis of many diseases. We also elaborate the different strategies used to manipulate the gut microbiota in the prevention and treatment of disorders. The future of medicine is strongly related to the quality of our microbiota. Targeting microbiota dysbiosis will be a huge challenge.

show abstract

Section: Therapeutic Strategies In the Gut Microbiota Manipulationmentioning

confidence: 80%

Microbiota medicine: towards clinical revolution

Gebrayel¹,

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Our previous work shows the remarkable efficacy of FMT in preventing colonization of a single, in that case, antibiotic-resistant bacteria ( 118 ). Also, in the model of graft-versus-host disease, we have shown that it is possible to stop the inflammatory process in the gut by FMT, shedding new light on the immunomodulatory effect of the gut microbiota ( 119 , 120 ). Given that single species of bacteria, Klebsiella and Streptococcus were shown to play a role in the progression of MM, it seems that further studies on gut microbiota in the treatment of MM are warranted.…”

Section: Discussionmentioning

confidence: 95%

The Role of the Crosstalk Between Gut Microbiota and Immune Cells in the Pathogenesis and Treatment of Multiple Myeloma

2022

Self Cite

View full text Add to dashboard Cite

Around 10% of all hematologic malignancies are classified as multiple myeloma (MM), the second most common malignancy within that group. Although massive progress in developing of new drugs against MM has been made in recent years, MM is still an incurable disease, and every patient eventually has relapse refractory to any known treatment. That is why further and non-conventional research elucidating the role of new factors in MM pathogenesis is needed, facilitating discoveries of the new drugs. One of these factors is the gut microbiota, whose role in health and disease is still being explored. This review presents the continuous changes in the gut microbiota composition during our whole life with a particular focus on its impact on our immune system. Additionally, it mainly focuses on the chronic antigenic stimulation of B-cells as the leading mechanism responsible for MM promotion. The sophisticated interactions between microorganisms colonizing our gut, immune cells (dendritic cells, macrophages, neutrophils, T/B cells, plasma cells), and intestinal epithelial cells will be shown. That article summarizes the current knowledge about the initiation of MM cells, emphasizing the role of microorganisms in that process.

show abstract

“…As the patients with gut GvHD are often colonized with antibiotic-resistant bacteria (ARB), there are pioneer studies of experience performing FMT in patients with acute or chronic GvHD, co-colonized with ARB. These studies have shown a good efficacy of FMT in the treatment of GvHD and decolonization of the GI tract from ARB [160,161].…”

Section: Graft-versus-host Diseasementioning

confidence: 93%

“…Complications from the procedure comprise most of all infections and GvHD, which are the major causes of morbidity and mortality (45% of attributable deaths) apart from relapse [160]. The first-line therapy in acute GvHD is systemic administration of high-dose glucocorticoids, but only 40-60% of patients respond to this treatment depending on the grade of severity of the disease [161]. At present, there is no established standard-of-care second-line therapy.…”

Section: Graft-versus-host Diseasementioning

confidence: 99%

“…At present, there is no established standard-of-care second-line therapy. The high mortality rate of steroid-refractory/dependent (sr/d) acute GvHD, especially in patients with grade III-IV lower gastrointestinal tract involvement, is a major drive for exploring novel therapeutic strategies [161,162]. As the patients with gut GvHD are often colonized with antibiotic-resistant bacteria (ARB), there are pioneer studies of experience performing FMT in patients with acute or chronic GvHD, co-colonized with ARB.…”

Section: Graft-versus-host Diseasementioning

confidence: 99%

See 1 more Smart Citation

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation

et al. 2022

View full text Add to dashboard Cite

The intestinal microbiota plays an important role in maintaining human health, and its alteration is now associated with the development of various gastrointestinal (ulcerative colitis, irritable bowel syndrome, constipation, etc.) and extraintestinal diseases, such as cancer, metabolic syndrome, neuropsychiatric diseases. In this context, it is not surprising that gut microbiota modification methods may constitute a therapy whose potential has not yet been fully investigated. In this regard, the most interesting method is thought to be fecal microbiota transplantation, which consists of the simultaneous replacement of the intestinal microbiota of a sick recipient with fecal material from a healthy donor. This review summarizes the most interesting findings on the application of fecal microbiota transplantation in gastrointestinal and extraintestinal pathologies.

show abstract

Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series

Cited by 16 publications

References 5 publications

Microbiota medicine: towards clinical revolution

Microbiota medicine: towards clinical revolution

The Role of the Crosstalk Between Gut Microbiota and Immune Cells in the Pathogenesis and Treatment of Multiple Myeloma

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation

Contact Info

Product

Resources

About